Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Prevnar 13

Known as: PCV-13 vaccine, prevenar 13, PCV13 vaccine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal… Expand
2016
2016
Background: Because Bangladesh intended to introduce pneumococcal conjugate vaccine (PCV)-10 in 2015, we examined the baseline… Expand
2015
2015
OBJECTIVES To describe the distribution of vaccine and non-vaccine pneumococcal serotypes from adult patients for different… Expand
  • table 1
  • figure 1
  • table 4
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
OBJECTIVE: To examine whether there is a different clinical profile and severity of invasive pneumococcal disease (IPD) in… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2014
Highly Cited
2014
Background: The direct impact of 13-valent pneumococcal conjugate vaccine (PCV13) on colonization with unique PCV13 serotypes and… Expand
2014
2014
BACKGROUND Before the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease (IPD) rates… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2012
Review
2012
Pneumococcus is the leading cause of bacterial illness in children worldwide. The development, clinical evaluation, and… Expand
2012
2012
Invasive pneumococcal disease (IPD) associated with Streptococcus pneumonia is a major public health problem worldwide for all… Expand
2011
2011
Objetivo: Analisis de coste-efectividad de la vacunacion antineumococica pediatrica en Espana. Metodos: Se utilizo un modelo… Expand
2002
2002
SummaryAbstractPNCRM7 (Prevnar™1) is a pneumococcal vaccine containing seven capsular polysaccharide antigens from the bacterium… Expand